SAN DIEGO, Dec. 7, 2022 /CNW/ -- Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today that Congruence's CEO, Dr. Clarissa Desjardins, will present a corporate overview at the Biotech Showcase 2023 meeting on Monday, January 9, 2023, at 3:30 PM. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41st Annual HealthCare Conference.
The Company will be available to meet potential partners, collaborators, and investors. One-to-one appointments may be requested as follows:
- The Biotech Showcase partnering platform: https://informaconnect.com/biotech-showcase/
- Biotechnology Innovation Organization (BIO) partnering platform: https://www.bio.org/events/bio-partnering-jpm
About Congruence Therapeutics
Congruence Therapeutics is a drug discovery company that is uniquely harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning, AI, and computational chemistry to advance drug discovery. Our ground-breaking discovery engine, RevenirTM, can reproduce the pathogenic state of disease and discover functional allosteric and cryptic pockets with an unprecedented timing and hit rate. RevenirTM sees proteins in ways others have been unable to see - in their full dynamic state.
For more information, please visit www.congruencetx.com.
Company Contact
Tanya Borsuk
EVP of Corporate and Business Development
[email protected]
Media Contact
Amy Conrad
Juniper Point
[email protected]
858-366-3243
SOURCE Congruence Therapeutics
Share this article